Browse drugs

… treatments were of very low certainty. For endoscopic relapse, vedolizumab probably reduced the risk of relapse (moderate certainty), RR 0…

… led to 43.2% clinical remission in an Emirati CD cohort, while tofacitinib achieved clinical remission rates of 56.4% and 61.1% at 52 week…

…licated by cytomegalovirus infection, successfully treated with valganciclovir. A repeat colonoscopy demonstrated complete mucosal healing and…

…(11%), with two commencing or escalating biologics (infliximab, vedolizumab) and one receiving a non-biologic adjustment. No surgical refer…

….This case highlights a rare but important dual complication of infliximab therapy in a paediatric patient—pneumonitis and hepatotoxicity—…

… receiving biologic therapy at the time of the audit, including infliximab in 47, adalimumab in 13, ustekinumab in 2, and vedolizumab in 1…

…b 44.3%, Adalimumab 27.9%, Vedolizumab 13.1%, Ustekinumab 9.8%, Golimumab 3.3% and Risankizumab 1.6%.The mean [±SD] gestational age at tr…

…reported in icotrokinra treatment groups through W12.Conclusion Icotrokinra, the first-in-class targeted oral peptide that selectively bloc…

…ommon recent drugs were adalimumab, infliximab, ustekinumab and vedolizumab. There were no significant differences between groups in potent…

… ≥2, and inadequate response/intolerance (IR) to TNFa blockers, vedolizumab, ustekinumab, JAK inhibitors, or S1P receptor modulators (BIO/J…

…ctors associated with obesity in patients with IBD treated with infliximab and vedolizumab across the United Kingdom (UK). Gut 2025;74:A12…

…e primary outcome was the association between time to first AT (Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab or Tofacitinib…